Insulin Treatment Attenuates Decline of Muscle Mass in Japanese Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Sarcopenia is defined as an age-related loss of skeletal muscle mass and strength, and is a major cause of disability and mobility limitations. Recent studies have demonstrated that type 2 diabetes and insulin signaling deficiencies contribute to the progression of sarcopenia, suggesting that a sufficient supply of insulin to the skeletal muscles may be important for the maintenance of muscle function; however, little has been reported regarding whether insulin treatment can protect against sarcopenia. We conducted a retrospective observational study to examine the impact of insulin treatment on the muscle mass of patients with type 2 diabetes. A total of 312 patients (mean age: 64 ± 11 years; 40.8% female; 27.6% treated with insulin) were studied in this retrospective observational study. Skeletal muscle index (SMI) and grip strength (kg) were used to assess sarcopenia. The prevalence of sarcopenia was 18.0%. Insulin treatment was shown to be protective against the annual decline of SMI (standardized β 0.195; p = 0.025) even after adjusting for covariates, including age, gender, duration of diabetes, and body mass index. In a cohort matched by propensity scores, insulin treatment significantly increased the 1-year change in SMI (mean ± SE) compared with non-insulin-treated group (2.40 ± 0.98% vs. -0.43 ± 0.98%; p = 0.050). Our data suggest that insulin treatment could attenuate the progression of sarcopenia in patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While existing clinical trial and epidemiological data demonstrate a positive correlation between insulin use and measures related to sarcopenia,43–45”
From Imaging of Sarcopenia in Type 2 Diabetes Mellitus (2024) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., Yamagata, K., Tomino, Y., Yokoyama, H., & Hishida, A. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.034 · Cited by 6,422
Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051 · cited 2×
“According to the Asian sarcopenia criteria [3], an SMI <7.”
BackgroundMethodFielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256 · cited 6×
“Sarcopenia occurs with advancing age (aging is the strongest contributor to the progression of sarcopenia); therefore, age differences could influence the outcome data, particularly regarding the effect of insulin treatment on muscle mass; however, insulin treatment was significantly associated with preserved muscle m…”
BackgroundMethodInfluentialRoberts, H. C., Denison, H. J., Martin, H. J., Patel, H. P., Syddall, H., Cooper, C., & Sayer, A. A. (2011) · Age and Ageing · doi:10.1093/ageing/afr051 · Cited by 3,001 · cited 1×
“to improve the assessment of sarcopenia [27].”
Fox, C. S., Massaro, J. M., Hoffmann, U., Pou, K. M., Maurovich-Horvat, P., Liu, C.-Y., Vasan, R. S., Murabito, J. M., Meigs, J. B., Cupples, L. A., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.675355 · Cited by 2,882
Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases
Kalyani, R. R., Corriere, M., & Ferrucci, L. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70034-8 · Cited by 1,102 · cited 2×
“Moreover, the presence of diabetes, poor glycemic control, and insulin resistance have been reported to increase the risk for lowering muscle mass and function in elderly individuals [5, 7, 8, 13, 26].”
BackgroundSkyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Cermak, N. M., Res, P. T., de Groot, L. C., Saris, W. H., & van Loon, L. J. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.037556 · Cited by 827 · cited 1×
“Resistance training with protein supplementation was reported to be the most effective form of treatment for sarcopenia, [9, 10].”
BackgroundExcessive Loss of Skeletal Muscle Mass in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Lee, J. S., Kuller, L. H., Boudreau, R., de Rekeneire, N., Harris, T. B., Kritchevsky, S., Tylavsky, F. A., Nevitt, M., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0264 · Cited by 778
Accelerated Loss of Skeletal Muscle Strength in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Strotmeyer, E. S., Kuller, L. H., Broudeau, R., Kammerer, C., de Rekeneire, N., Harris, T. B., Schwartz, A. V., Tylavsky, F. A., et al. (2007) · Diabetes Care · doi:10.2337/dc06-2537 · Cited by 766
Decreased Muscle Strength and Quality in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Strotmeyer, E. S., de Rekeneire, N., Harris, T. B., Schwartz, A. V., Tylavsky, F. A., & Newman, A. B. (2006) · Diabetes · doi:10.2337/db05-1183 · Cited by 751
Body Fat Distribution, Incident Cardiovascular Disease, Cancer, and All-Cause Mortality
Britton, K. A., Massaro, J. M., Murabito, J. M., Kreger, B. E., Hoffmann, U., & Fox, C. S. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.06.027 · Cited by 688 · cited 1×
“Moreover, the presence of diabetes, poor glycemic control, and insulin resistance have been reported to increase the risk for lowering muscle mass and function in elderly individuals [5, 7, 8, 13, 26].”
BackgroundLeenders, M., Verdijk, L. B., van der Hoeven, L., Adam, J. J., van Kranenburg, J., Nilwik, R., & van Loon, L. J. C. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.02.006 · Cited by 480 · cited 1×
“The accumulation of body fat, particularly abdominal visceral fat, has been recognized as a strong contributor to the development of CVD and metabolic disorders, including diabetes [24, 25].”
BackgroundRole of muscle mass and muscle quality in the association between diabetes and gait speed
Volpato, S., Bianchi, L., Lauretani, F., Lauretani, F., Bandinelli, S., Guralnik, J. M., Zuliani, G., & Ferrucci, L. (2012) · Diabetes Care · doi:10.2337/dc11-2202 · Cited by 294
Hyperglycemia Predicts Persistently Lower Muscle Strength With Aging
Kalyani, R. R., Metter, E. J., Egan, J., Golden, S. H., & Ferrucci, L. (2015) · Diabetes Care · doi:10.2337/dc14-1166 · Cited by 236
Insulin sensitizers may attenuate lean mass loss in older men with diabetes
Lee, C. G., Boyko, E. J., Barrett-Connor, E., Miljkovic, I., Hoffman, A. R., Everson-Rose, S. A., Lewis, C. E., Cawthon, P. M., Strotmeyer, E. S., Orwoll, E. S., et al. (2011) · Diabetes Care · doi:10.2337/dc11-1032 · Cited by 168
Fujita, S., Glynn, E. L., Timmerman, K. L., Rasmussen, B. B., & Volpi, E. (2009) · Diabetologia · doi:10.1007/s00125-009-1430-8 · Cited by 164 · cited 1×
“Furthermore, supraphysiological hyperinsulinemia has been reported to be necessary for the stimulation of muscle protein synthesis and anabolic signaling in elderly subjects [16], suggesting that sufficient insulin supply could provide protection against the progression of sarcopenia in patients with diabetes.”
BackgroundMensink, M., Hesselink, M. K. C., Russell, A. P., Schaart, G., Sels, J.-P., & Schrauwen, P. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803567 · Cited by 160
Kalyani, R. R., Tra, Y., Yeh, H., Egan, J. M., Ferrucci, L., & Brancati, F. L. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12204 · Cited by 147 · cited 3×
“Although the protective mechanism of insulin on the progression of muscle dysfunction that was dominant in the lower extremities remains unclear, some previous reports provide important speculation [21, 22].”
BackgroundResultInfluentialMavros, Y., Kay, S., Anderberg, K. A., Baker, M. K., Wang, Y., Zhao, R., Meiklejohn, J., Climstein, M., O’Sullivan, A., de Vos, N., et al. (2013) · Diabetes Care · doi:10.2337/dc12-2196 · Cited by 118 · cited 1×
“In diabetic patients, poor glycemic control and insulin resistance are independently associated with the decline of skeletal muscle mass among elderly patients with diabetes [12, 13].”
BackgroundSarcopenia: A useful paradigm for physical frailty
Cruz-Jentoft, A. J., & Michel, J. (2013) · European Geriatric Medicine · doi:10.1016/j.eurger.2013.02.009 · Cited by 82 · cited 1×
“Although it has been clearly shown that sarcopenia has an adverse effect on mobility, the quality of life (QOL), and mortality [2, 4], the diagnostic thresholds of muscle mass and strength remain controversial.”
BackgroundComprehensive Approach to Sarcopenia Treatment
Wakabayashi, H., & Sakuma, K. (2014) · Current Clinical Pharmacology · doi:10.2174/1574884708666131111192845 · Cited by 69 · cited 1×
“Resistance training with protein supplementation was reported to be the most effective form of treatment for sarcopenia, [9, 10].”
BackgroundTanaka, K.-I., Kanazawa, I., & Sugimoto, T. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-9990-8 · Cited by 63 · cited 1×
“In addition, low endogenous insulin secretion was also associated with muscle mass among patients with diabetes [15].”
BackgroundPackianathan, I., Fuller, N. J., Peterson, D. B., Wright, A., Coward, W. A., & Finer, N. (2005) · Diabetologia · doi:10.1007/s00125-004-1642-x · Cited by 38
Pharmaceutical Interventions for Frailty and Sarcopenia
Laosa, O., Alonso, C., Castro, M., & Rodríguez‐Mañas, L. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660705 · Cited by 33 · cited 1×
“Pharmaceutical therapies have also been studied; however, there is insufficient evidence supporting effective medication for the treatment of sarcopenia [11].”
BackgroundEffect of insulin treatment on the body composition of Type 2 diabetic patients
Salle, A. D., Guilloteau, G., Ryan, M. M., Bouhanick, B., & Ritz, P. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01335.x · Cited by 31
Cited by
A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors
Izzo, A., Massimino, E., Riccardi, G., & Della Pepa, G. (2021) · Nutrients · doi:10.3390/nu13010183 · Cited by 418
“[55] retrospective 312 M/W 64 years 24.”
Impact of diabetes on sarcopenia and mortality in patients undergoing hemodialysis
Mori, K., Nishide, K., Okuno, S., Shoji, T., Emoto, M., Tsuda, A., Nakatani, S., Imanishi, Y., Ishimura, E., Yamakawa, T., et al. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1271-8 · Cited by 152
Inactivity and Skeletal Muscle Metabolism: A Vicious Cycle in Old Age
Rezuş, E., Burlui, A., Cardoneanu, A., Rezuş, C., Codreanu, C., Pârvu, M., Rusu Zota, G., & Tamba, B. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020592 · Cited by 116
Massimino, E., Izzo, A., Riccardi, G., & Della Pepa, G. (2021) · Cells · doi:10.3390/cells10081958 · Cited by 102
Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications
Zhang, X., Zhao, Y., Chen, S., & Shao, H. (2021) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12838 · Cited by 92
Metadata
- Authors
- Bouchi, R., Fukuda, T., Takeuchi, T., Nakano, Y., Murakami, M., Minami, I., Izumiyama, H., Hashimoto, K., Yoshimoto, T., & Ogawa, Y.
- Affiliations
- Tokyo Medical and Dental University (JP)
- Corresponding author
- Bouchi, Ryotaro
- ORCID
- Venue
- Calcified Tissue International
- Published
- 2017-02-28
- Volume
- 101
- Issue
- 1
- Pages
- 1-8
- ISSN
- 0171-967X (ISSN-L)
- 1432-0827
- PMC
- PMC5486921
- OpenAlex
- W2593371426
- Cited by
- 64
- References
- 27
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 10 · 2023: 13 · 2022: 12 · 2021: 8 · 2020: 6 · 2019: 5 · 2018: 1
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Calcified Tissue International (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- insulin therapy, sarcopenia, type 2 diabetes, skeletal muscle mass, skeletal muscle index, grip strength, muscle mass loss, insulin resistance, Japanese patients
- MeSH terms
- Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Retrospective Studies, Muscle, Skeletal, Young Adult, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.